Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 11/20 | 0.35 |
| ▸ | MAOA | P21397 | 6/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18875720 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL18875595 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL18875585 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL18875721 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL14505233 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL18875706 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL14505238 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL18875597 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL18875598 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA | |
| SCHEMBL18875659 | 0.89 | POLB (0.39) | SMN1; SMN2MAOBMAOAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | SMN1; SMN2 3883/4885MAOB 2274/4885MAOA 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.